Reduced tissue and serum resistin expression as a clinical marker for esophageal squamous cell carcinoma
| Autor: | Je-Kang Du, Yen-Yun Wang, Michael Yuanchien Chen, Kun-Tsung Lee, Stephen Chu-Sung Hu, Amos C. Hung, Hung-Hsing Chiang, Yuk-Kwan Chen, Kwei-Jing Chen, Chun-Ming Chen, Shyng-Shiou F. Yuan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
endocrine system diseases Receptor expression toll-like receptor 4 adipocytokine Adipose tissue body mass index Medicine esophageal cancer adenylyl cyclase-associated protein 1 resistin Oncogene business.industry nutritional and metabolic diseases Cancer Articles respiratory system Cell cycle Esophageal cancer medicine.disease Molecular medicine digestive system diseases Oncology Cancer research Resistin business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2021.13035 |
| Popis: | Esophageal cancer is one of the most common malignancies and leading cause of cancer-associated mortality worldwide. However, the molecular mechanisms underlying esophageal cancer progression and the development of clinical tools for effective diagnosis remain unclear. Resistin, which was originally identified as an adipose tissue-secretory factor, has been associated with obesity-related diseases, including certain types of cancer. Thus, the present study aimed to investigate the expression levels of resistin in tissue and serum specimens from patients with esophageal squamous cell carcinoma (ESCC) to determine the potential biological effects of resistin on ESCC cells. The results demonstrated that both tissue and serum resistin levels were significantly lower in patients with ESCC compared with healthy controls. In addition, resistin expression was positively associated with the body mass index of patients with ESCC. In vitro studies revealed that resistin inhibited the migratory ability of ESCC cells, while having no effect on ESCC cell proliferation. Taken together, these results suggest that resistin may have the potential to be developed into a clinical marker for ESCC. However, further studies are required to investigate resistin receptor expression and determine the potential involvement of resistin-associated biological pathways, which may provide insight for future development of targeted therapies for resistin-mediated ESCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|